Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$827.72-1.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · REGN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks REGN against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue progressing nearly 50 clinical-stage product candidates, securing regulatory approvals and expanding indications across multiple therapeutic areas.
Stated as a priority in 6 of last 6 quarters. Regeneron consistently reported approximately 45 to 50 clinical-stage product candidates, with recent regulatory approvals for Dupixent, EYLEA HD, Libtayo, and Otarmeni. The company is delivering on advancing its pipeline with multiple new approvals and ongoing late-stage trials, demonstrating steady progress.
“Regeneron has approximately 50 product candidates in clinical development, including marketed products with additional indications.”
“Nearly 50 product candidates in clinical development, including marketed products with additional indications.”
“Approximately 45 product candidates in clinical development, including marketed products with additional indications.”
“Approximately 45 product candidates in clinical development, including marketed products with additional indications.”
“Approximately 45 product candidates in clinical development, including marketed products with additional indications.”
“Approximately 45 product candidates in clinical development, including marketed products with additional indications.”
Sustain and expand sales of core products Dupixent, EYLEA HD, and Libtayo through label expansions, increased demand, and market penetration.
Stated as a priority in 6 of last 6 quarters. Dupixent global net sales grew from $3.67B in 2025-Q1 to $6.0B in 2026-Q2, EYLEA HD U.S. net sales increased from $307M to $596M, and Libtayo global net sales rose from $285M to $489M over the same period. Management consistently emphasized growth in these key products, and the financials show delivering strong sales expansion.
Continue returning capital to shareholders through share repurchase programs and quarterly cash dividends while investing in pipeline and manufacturing.
Stated as a priority in 6 of last 6 quarters. Regeneron consistently returned capital via share repurchases totaling over $2 billion in the first half of 2026 and declared quarterly dividends of $0.94 per share in mid-2026. Available repurchase capacity remained substantial at $2.5 billion as of June 30, 2026. Management is delivering on capital allocation commitments.
Sustain GAAP gross margin on net product sales in the range of 77% to 79% for fiscal year 2026 despite temporary manufacturing interruptions.
Stated as a priority in 6 of last 6 quarters. GAAP gross margin on net product sales decreased from approximately 83% in 2025-Q2 to 78% in 2026-Q2, reflecting temporary manufacturing interruptions. Management updated 2026 guidance to 77%-79%, indicating limited progress in margin recovery but consistent communication of the impact.
“GAAP gross margin on net product sales guidance updated to 77%-79% for 2026 due to temporary manufacturing interruption.”
Maintain GAAP effective tax rate guidance in the range of 12% to 14% for fiscal year 2026, managing tax liabilities and benefits.
Stated as a priority in 6 of last 6 quarters. GAAP effective tax rate increased from 8.4% in 2025-Q2 to 15.1% in 2026-Q2, exceeding the guided range of 12%-14%. Management maintained guidance at 12%-14% for 2026, but actual rates have been higher recently, indicating limited progress in controlling the tax rate.
“GAAP effective tax rate guidance 12%-14% for 2026.”
Over the trailing year it converted 1.38x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
1 material management or governance event in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“Dupixent global net sales increased 38%, Libtayo global net sales increased 30%, and EYLEA HD U.S. net sales increased 52% versus prior year.”
“Dupixent global net sales increased 33%, Libtayo global net sales increased 54%, and EYLEA HD U.S. net sales increased 52% versus prior year.”
“Dupixent global net sales increased 34%, Libtayo global net sales increased 16%, and EYLEA HD U.S. net sales increased 66% versus prior year.”
“Dupixent global net sales increased 27%, Libtayo global net sales increased 26%, and EYLEA HD U.S. net sales increased 10% versus prior year.”
“Dupixent global net sales increased 22%, Libtayo global net sales increased 27%, and EYLEA HD U.S. net sales increased 29% versus prior year.”
“Dupixent global net sales increased 19%, Libtayo global net sales increased 8%, and EYLEA HD U.S. net sales increased 54% versus prior year.”
“Deployed $2.0 billion in share repurchases in first half 2026; $2.5 billion remains available for repurchases.”
“Repurchased $803 million of common stock in Q1 2026; new $3.0 billion share repurchase program authorized in April 2026.”
“Repurchased $671 million in Q4 2025; $1.5 billion available for repurchases at year-end.”
“Repurchased $663 million in Q3 2025; $2.156 billion available for repurchases at quarter-end.”
“Repurchased $1.07 billion in Q2 2025; $2.814 billion available for repurchases at quarter-end.”
“Repurchased $1.052 billion in Q1 2025; $3.874 billion available for repurchases at quarter-end.”
“GAAP gross margin on net product sales guidance 78%-80% for 2026.”
“GAAP gross margin on net product sales approximately 83% for 2025.”
“GAAP gross margin on net product sales approximately 82% for 2025.”
“GAAP gross margin on net product sales approximately 83% for 2025.”
“GAAP gross margin on net product sales approximately 83% for 2025.”
“GAAP effective tax rate guidance 12%-14% for 2026.”
“GAAP effective tax rate approximately 14% for 2025.”
“GAAP effective tax rate approximately 14% for 2025.”
“GAAP effective tax rate 11%-13% for 2025.”
“GAAP effective tax rate 12.5% in 2026-Q1.”